Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)

Koji Nagafuji, Itaru Matsumura, Takayuki Shimose, Tatsuya Kawaguchi, Junya Kuroda, Hirohisa Nakamae, Toshihiro Miyamoto, Norimitsu Kadowaki, Jun Ishikawa, Yutaka Imamura, Hirohito Yamazaki, Koichi Akashi, Yuzuru Kanakura

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Fingerprint Dive into the research topics of 'Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)'. Together they form a unique fingerprint.

Medicine & Life Sciences